Zum Inhalt springen

Saudi Arabia’s Biotech Revolution

The Most Innovative Companies Leading the Way. Saudi Arabia is rapidly emerging as a global biotechnology hub, driven by its ambitious Vision 2030 initiative. The country is investing heavily in research and development, infrastructure, and talent acquisition to create a thriving ecosystem for biotech companies. Here are some of the most innovative Saudi biotech companies leading the charge: 1. SAUDIBIO: The first and only GMP-certified biotech manufacturing facility in Saudi Arabia, SAUDIBIO is a joint stock company focused on producing biopharmaceutical products, including recombinant human insulin and biosimilars. The company has partnered with global giants like Novo Nordisk to drive innovation and growth[1]. 2. Sana Biotechnology: A prominent player in the Saudi biotech sector, Sana Biotechnology is dedicated to developing cutting-edge biotechnology products and services. The company is known for its innovative approach to agricultural biotechnology, focusing on crop optimization… 

more »Saudi Arabia’s Biotech Revolution

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of… Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis The post Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma appeared first on Bio Tech Winners. Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) — Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) will be featured in three scientific presentations at the 2024 joint annual meeting for the American Society for Clinical Laboratory Science (ASCLS), the Association of Genetic Technologists… Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations

Spectral AI Achieves 100% Pediatric Enrollment in Burn Centers for Pivotal U.S. Burn Study

DALLAS, July 02, 2024 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has achieved 100% pediatric patient enrollment at burn centers for its 2024 pivotal study designed… Spectral AI Achieves 100% Pediatric Enrollment in Burn Centers for Pivotal U.S. Burn Study

Mainz Biomed Provides Half Year 2024 Corporate Update

Mainz Biomed Provides Half Year 2024 Corporate Update – Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study The post Mainz Biomed Provides Half Year 2024 Corporate Update appeared first on Bio Tech Winners. Mainz Biomed Provides Half Year 2024 Corporate Update

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of… HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

Dawn Health and Merck are collaborating to support Growth Disorders care

Dawn Health, the digital health company pioneering patient-first innovation, has announced they are working with leading global pharmaceutical company, Merck, on a digital solution for Growth Hormone Disorders (GHD). Over the next two years, they will join forces to deliver a cutting-edge, user-centric digital platform, designed to help improve the lives […] Dawn Health and Merck are collaborating to support Growth Disorders care

Weleda: Mónica Mennet-von Eiff wird Chief Pharma Officer

Arlesheim / Schwäbisch Gmünd (ots) – Mit der Berufung von Dr. Mónica Mennet-von Eiff (59) zur Chief Pharma Officer und Mitglied der Geschäftsleitung stellt der Verwaltungsrat der Weleda AG die Weichen weiter in Richtung Zukunft. Weleda Verwaltungsratspräsident Thomas Jorberg, der zuletzt innerhalb der Geschäftsleitung ad interim das Weleda Pharma Business verantwortete, hat die Pharma-Leitung an […] Weleda treibt Neuausrichtung der Arzneimittelsparte weiter voran: Dr. Mónica Mennet-von Eiff wird Chief Pharma Officer

Geschlechtsspezifische Unterschiede bei Diabetes

Zwei Jahre länger als bei Männern dauert es im Schnitt, bis Frauen erfahren, dass sie Typ-2-Diabetes haben. Das ist aber nicht der einzige Unterschied: Frauen leiden häufiger an Nebenwirkungen von Arzneien und ihr Zyklus beeinflusst die Wirksamkeit der Insulintherapie. Die Geschlechter bei Diabetes gleich zu behandeln, kann sogar gefährlich sein. Sind Frauen im Nachteil? Diese spannende Frage beantwortet die neue Ausgabe des Apothekenmagazins „Diabetes Ratgeber“. Die Risikofaktoren sind zwar für Männer und Frauen die gleichen, doch Studien belegen: Männer erkranken weltweit etwas häufiger an Typ-2-Diabetes, dafür ist die Krankheit bei Frauen ein größerer Risikofaktor für Herz-Kreislauf-Erkrankungen wie Herzinfarkt oder Schlaganfall. Zudem sind Frauen bei der Diagnose durchschnittlich etwas älter. Das liegt an den Hormonen: Nach den Wechseljahren steigt das Risiko für Typ-2- Diabetes stark an. „Es gibt viele verschiedene Typen und Ausprägungen von Diabetes. Wesentlich sind aber die Sexualhormone“, sagt… 

more »Geschlechtsspezifische Unterschiede bei Diabetes